目的 探讨多柔比星长循环脂质体经乳腺导管给药后患者体内血药浓度变化的情况。方法 15名女性乳腺癌患者随机分为50、20、10 mg 3个剂量组，经乳腺导管给药，于规定的时间点采集外周静脉血，通过本实验室建立的高效液相荧光检测法测定血药浓度。结果 低剂量和中剂量组血样采集时间最长至给药后96 h，给药后72 h血药浓度平均值分别达到852.91和1 148.59 ng·mL-1，高剂量组血样采集至用药后72 h，血药浓度平均值达到3 921.88 ng·mL-1。结论 患者体内血药浓度与多柔比星长循环脂质体乳腺导管给药量之间存在正相关性；与传统的外周静脉滴注相比，经乳腺导管给药后，多柔比星长循环脂质体呈现不同的药动学特征。
Abstract
OBJECTIVE To study the distribution of doxorubicin in human blood after intraductal administration. METHODS Doxorubicin long-circulating liposome was given through intraductal administration in three different dose groups of 10, 20 and 50 mg to 15 female breast cancer patients randomly, and blood was collected and the concentration was determined by HPLC with fluorescence detector. RESULTS In the group treated with low and middle doses, the blood samples were collected for 96 h after administration, and the average plasma concentrations at 96 h were 760.26 and 1 199.90 ng·mL-1 respectively. In the group treated with high dose, the blood samples were collected for 72 h after administration, and the average plasma concentration of doxorubicin was 3 921.88 ng·mL-1 at 72 h. CONCLUSION The plasma concentration of doxorubicin was positively correlated with the dosage. Compared with intravenous injection, the pharmacokinetic profile of doxorubicin long-circulating liposome shows significant difference.
关键词
多柔比星长循环脂质体 /
给药方式 /
血药浓度 /
高效液相色谱法
{{custom_keyword}} /
Key words
doxorubicin long-circulating liposome /
intraductal administration /
plasma concentration of medication /
HPLC
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] GABIZON A, CANTANE R, UZIELY B , et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes[J]. Cancer Res, 1994,54（4）:987-992.
[2] WORKING P K, DAYAN A D. Pharmacological-toxicological expert report: CaelixTM (Stealth liposomal doxorubicin HCl)[J]. Hum Exper Toxicol, 1996,15(9):752-785.
[3] GABIZON A, MARTIN F. Polyethylene glycol-coated (Pegylated) liposomal Doxorubicin[J]. Drugs, 1997,54(Suppl 4):15-21.
[4] SAFRA T, MUGGIA F, JEFFERS S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg·m-2[J]. Ann Oncol, 2000, 11(8):1029-1033.
[5] BERRY G, BILLINGHAM M, ALDERMAN E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin[J]. Ann Oncol, 1998, 9(7):711-716.
[6] MARINA N M, COCHRANE D, HARNEY E, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: A pediatric oncology group study[J]. Clin Cancer Res, 2002, 8（2）:413-418.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(635 KB)
